N/A N=399 Instrument Precision Study for Validation of Philips Dx
Pathology
Primary: Agreement Rate — 92.0; 93.8 percentage of agreement
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 2 N=178 Safety and Efficacy of GS-4774 for the Treatment of Chronic Hepatitis B
Chronic HBV Infection
Primary: Change From Baseline in HBsAg at Week 24 — -0.019; -0.020; -0.026; -0.048 log10 IU/mL — p=0.976
N/A N=20 The Influence of Stability Boots on Gait Pattern in Healthy Adults
Rehabilitation After Ankle Injuries
Primary: ROM Ankle Joint — 31.4; 18.4; 21.2 degree
N/A N=43 Benefit of Adding Stretching to Standard Intervention For Patients With Nonspecific Mechanical Neck Pain
Neck Pain
Primary: Cervical Range of Motion — 46.2; 46.1; 71.2; 68.5 Degree
Phase 1 N=13 The Maraviroc Darunavir/Ritonavir Once Daily Pharmacokinetic Study
HIV
Primary: The Ratio of the Maximum Plasma Concentration of Maraviroc Between 20 and 10 Day — 0.99 ratio
Phase 4 N=326 Efficacy and Safety of the Ophthalmic Solution PRO-087 Versus Systane ® Ultra and Ultra Preservative Free (087LATAMFIV)
Dry Eye Syndrome
Primary: Visual Acuity — 0.187; 0.215; 0.219; 0.172 LogMAR — p=0.080
N/A N=18 Airway Smooth Muscle and Asthma Severity
Asthma
Primary: Difference in ASM Mass Between Groups
Phase 2 N=45 Phase II Study of GIVINOSTAT (ITF2357) in Combination With Hydroxyurea in Polycythemia Vera
Polycythemia Vera
Primary: Percentage of Patients With Overall Haematological Response at Week 12. — 54.5; 50.0; 45.5; 50.0 percentage of particpants
N/A N=656 Patient Reported Outcomes Burdens and Experiences - Phase 2
Hemophilia
Primary: Response Rate — 656 Questionnaires
Phase 1 N=38 OTR Tablet 40 mg Fasted-state Bioequivalence Study
Chronic Pain
Primary: Cmax of OTR Tablet 40 mg and OXYCONTIN Tablet 40 mg in a Fasted State — 60.98; 52.23 ng/mL
Phase 1 N=14 Treatment Development for Glucose Transporter Type I Deficiency Syndrome (G1D)
Glucose Transporter Type 1 Deficiency Syndrome · GLUT1 Deficiency Syndrome
Primary: Number of Participants With Reduction in Spike-wave Fraction of the EEG Recording Time — 13 Participants
N/A N=301 Fibromyalgia Activity Study With Transcutaneous Electrical Nerve Stimulation (FAST)
Fibromyalgia
Primary: Pain Rating With Movement (0-10 Low to High Scale) During Six Minute Walk Test — -1.8; -0.8; 0.00; -2.0 Units on a scale — p=0.008
Phase 3 N=1,272 This Study Will Evaluate the Immunogenicity, Reactogenicity and Safety of the Routine Infant Vaccines Pediarix®, Hiberix® and Prevenar 13® When Co-administered With GlaxoSmithKline (GSK) Biologicals' Liquid Human Rotavirus Vaccine (HRV) as Compared to GSK's Licensed Lyophilized Vaccine
Rotavirus Infection · Rotavirus Vaccines
Primary: Number of Seroprotected Subjects With Anti-diphtheria (Anti-D) and Anti-tetanus (Anti-T) Antibody Concentrations Above or Equal to Cut-off Value. — 478; 486; 486; 495…
Phase 2 N=109 BELIEF (Bevacizumab and ErLotinib In EGFR Mut+ NSCLC)
Lung Cancer
Primary: Progression Free Survival — 16; 10.5 months
Phase 2 N=5 A Phase I/II Safety and Tolerability Dose Escalation Study of Autologous Stem Cells to Patients With Liver Insufficiency
Liver Disease
Primary: Number of Patients Who Tolerated the Maximum Dose — 5 Participants